Promising combo tackles rare blood cancer in chinese patients

NCT ID NCT05673785

Ongoing Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants receive the drugs through an IV and oral pills over 21-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone
What this could lead to: If successful, this could provide a new first-line treatment option for Chinese patients with CD30+ peripheral T-cell lymphoma, potentially improving response rates.
What could go wrong: This is a small, single-arm phase 2 trial with no placebo group, so results may not be definitive. Side effects from the chemotherapy combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-NEGATIVE SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-negative anaplastic large cell lymphoma ALK-positive anaplastic large cell lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma hepatosplenic T-cell lymphoma lymphoma peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

Anhui Provincial Cancer Hospital

Hefei, 230088, China
Beijing Cancer Hospital

Beijing, 100142, China
Chongqing University Cancer Hospital

Chongqing, 400030, China
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
Fujian Medical University Union Hospital

Fuzhou, 350001, China
Guangdong Provincial Peoples Hospital

Guangzhou, 510080, China
Henan Cancer Hospital

Zhengzhou, 450003, China
Peking University Third Hospital

Beijing, 100191, China
Shandong Cancer Hospital

Jinan, 250117, China
Shengjing Hospital of China Medical University

Shenyang, 110022, China
The First Affiliated Hospital of Nanchang University

Nanchang, 330006, China
The First Affiliated Hospital of Soochow University

Suzhou, 215004, China
The First Affiliated Hospital of Zhejiang University school of medicine

Hangzhou, 310003, China
The First Hospital of Jilin University

Changchun, 130021, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, 300060, China
West China Hospital, Sichuan University

Chengdu, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.